Untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma
Clinical trials for Untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma explained in plain language.
Never miss a new study
Get alerted when new Untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma trials appear
Sign up with your email to follow new studies for Untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug pumitamig takes on nivolumab in stomach cancer showdown
Disease control Recruiting nowThis study compares two drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that hasn't been treated yet. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combo works b…
Matched conditions: UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Phase 2/3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New pfizer combo aims to outperform current therapy for stomach cancer
Disease control Recruiting nowThis study tests a new experimental drug, PF-08634404, combined with chemotherapy in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new…
Matched conditions: UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Phase 2/3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC